Form 4: Director Ian T. Clark Increases Stake in Kyverna
Statement of Changes in Beneficial Ownership
Director Ian T. Clark acquired 5,093 restricted stock units and 20,582 stock options in Kyverna Therapeutics, Inc.
Summary
- Director Ian T. Clark was granted 5,093 restricted stock units (RSUs) of common stock.
- Director Ian T. Clark was granted stock options to purchase 20,582 shares at an exercise price of $8.59.
- Both the RSUs and the stock options are scheduled to vest in full on May 27, 2027, or immediately prior to the 2027 annual meeting of stockholders, whichever occurs first.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine disclosure of director compensation, which is neutral in terms of immediate market impact.
Positives
- Director alignment with shareholder interests through equity-based compensation.
- Equity grants are subject to continuous service requirements, incentivizing long-term retention.
Negatives
- The issuance of new equity awards results in potential future dilution for existing shareholders.
Risks
- Vesting is contingent upon the director's continuous service to the issuer.
Future Outlook
The equity awards are subject to vesting conditions based on continued service through May 2027.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to align board incentives with long-term corporate performance and shareholder value.
Comparison to Industry Standards
- The use of time-based vesting for director equity is consistent with standard corporate governance practices for publicly traded biotech firms.
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual vesting and exercise of these equity awards.
Next Steps
- Vesting of equity awards on May 27, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/27/2026 | Date of the earliest transaction and grant date for RSUs and options. |
| 05/29/2026 | Date the Form 4 was signed and filed. |
| 05/27/2027 | Vesting date for the RSUs and stock options. |
| 05/27/2036 | Expiration date for the stock options. |
Keywords
Kyverna Therapeutics, KYTX, Insider Trading, Form 4, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.